About

We are a young and creative company
offering fresh business ideas
bt_bb_section_bottom_section_coverage_image

We are Norcliffe Capital

With several decades of combined business experience in the life science and disruptive technology sectors, Norcliffe Capital provides more than capital to support our investments.

We use our experience and expertise to select UK based growth companies in our specialist sectors and support them throughout their commercial journey.

Operating across the UK, we source companies with proven IP aiming to make a material impact in their industry, within a growing global market, where there is a clearly defined consumer need. Our investments are usually uncorrelated to the traditional investment markets and have a range of exit routes which offer the potential of generating positive investor returns.

Norcliffe Capital works with financial advisers, wealth managers, family offices, private banks, accountants and individuals who are looking to directly invest in innovative UK companies within the life science and disruptive technology sectors with the potential to achieve exponential growth. Norcliffe Capital offers tax efficient ways to invest via the Enterprise Investment Scheme (EIS), SIPP, SSAS or a family investment company, as well as on a direct equity basis.

2015

Norcliffe Capital established

New office in Cheshire

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2016

Orsus Medical seed fundraise

NeedleSmart seed fundraise

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2017

Orsus Medical pre-series A fundraise

NeedleSmart pre-series A fundraise

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2018

February 2018

Norcliffe Capital is incorporated

NeedleSmart series A fundraise

November 2018

Norcliffe becomes an appointed representative of Sturgeon Ventures LLP

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2019

New office in East Sussex

Professor David Onions joins the team

Wi-Fi Securities seed fundraise

NeedleSmart series B fundraise

Afon Technology seed fundraise

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2020

Wi-Fi Securities pre-series A fundraise

Biosceptre International series A fundraise

Afon Technology series A fundraise

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2021

ClinSpec Diagnostics fundraise

Afon Technology series B fundraise

TOTAL FUNDRAISE £28.8 MILLION

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]
SELECT
We are highly selective and undertake rigorous due diligence before proceeding to invest.
90%
Financing Options
85%
Financing Solutions
https://www.norcliffe.capital/wp-content/uploads/2020/08/floating_image_03.png
https://www.norcliffe.capital/wp-content/uploads/2020/08/floating_image_05.png

We have a strict investment mandate

Norcliffe Capital offers investors the opportunity to directly invest in individual private companies in the life science and disruptive technology sectors.
bt_bb_section_top_section_coverage_image
bt_bb_section_bottom_section_coverage_image
https://www.norcliffe.capital/wp-content/uploads/2020/08/floating_image_04.png
https://www.norcliffe.capital/wp-content/uploads/2021/04/approach.png

Our Approach

Providing direct investment in ground-breaking life science and technology companies.

With decades of combined business experience in the life science and technology sectors, Norcliffe Capital provides more than capital to support our investments. We use our experience and expertise to select UK based growth companies in our specialist sectors and support them throughout their commercial journey.

We source companies with proven IP aiming to make a material impact in their industry. Our investments are usually uncorrelated to the traditional investment markets and have a range of exit routes to generate positive investor returns.

bt_bb_section_top_section_coverage_image

Our Team

We combine global expertise and local insight to help you
https://www.norcliffe.capital/wp-content/uploads/2021/04/patricia-ceo-norcliffe.jpg
It is such a privilege to support the next generation of life science technology. Our investments focus on meaningful causes that enhance the healthcare journey, save costs or save lives. Having more insight into medtech, biotech and pharmaceutical developments over the past few years has been an eye opener for me and revealed how truly talented our UK scientists and business leaders are. We see hundreds of innovations each year but unfortunately we can’t support them all.
Patricia Reynolds, CEO

Norcliffe Capital team is a diverse network of consultants and industry professionals with a global mindset and a collaborative culture. We work to understand your issues and are driven to ask better questions in the pursuit of making your business work better.

bt_bb_section_top_section_coverage_image
bt_bb_section_bottom_section_coverage_image